# A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

> **NCT00207025** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 60 (—)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** BMS-275183

## Key facts

- **NCT ID:** NCT00207025
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** 60 (—)
- **Last updated:** 2010-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00207025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00207025, "A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00207025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*